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ABSTRACT
In comparison to sporadic Creutzfeldt–Jakob disease (sCJD) with MM1-type and MM2- cortical
(MM2C)-type, genetic CJD with a prion protein gene V180I mutation (V180I gCJD) is clinically
characterized by onset at an older age, slower progress, and the absence of visual disturbances or
cerebellar symptoms. In terms of pathological characteristics, gliosis and neuronal loss are generally
milder in degree, and characteristic spongiform change can be observed at both the early and
advanced stages. However, little is known on the progress of spongiform change over time or its
mechanisms. In this study, to elucidate the pathological course of V180I gCJD, statistical analysis of
the size and dispersion of the major diameters of vacuoles in six V180I gCJD cases was performed,
with ﬁve MM1-type sCJD and MM2C-type sCJD cases as controls. As a result, V180I gCJD showed no
signiﬁcant difference in vacuolar diameter regardless of disease duration. In addition, the dispersion
of the major diameters of vacuoles in V180I gCJD was larger than that in the MM1-type, which was
smaller than that in the MM2C-type. We speculated that the absence of difference in the size of the
vacuoles regardless of disease duration suggests that tissue rarefaction does not result from the
expansion of vacuole size and increase in number of vacuoles in V180Ig CJD. These features were








Genetic Creutzfeldt–Jakob disease (gCJD) with a prion
protein (PrP) gene V180I mutation (V180I gCJD) is the
most common type of genetic CJD in Japan [1].
Although there have been several past reports on the
pathological ﬁndings observed in V180I gCJD, much of
its pathological progression remains unknown.
V180I gCJD is distinguished by the following clinical
characteristics in comparison to sporadic CJD (sCJD): the
age of onset is older (mean age: 72.8 years, range: 58–
81 years), the progress is slower, higher cortical dysfunc-
tions such as aphasias are observed, and visual disturban-
ces or cerebellar symptoms are absent, which are
important for diagnosing sCJD [2–4]. V180I gCJD is also
characterized by the absence of a family history or notable
myoclonus, and the lack of periodic sharp-wave com-
plexes (PSWC) on the electroencephalogram (EEG) [2–4].
Fine small round vacuoles with clear boundaries have
been observed in MM1-type sCJD. At cerebral patho-
logic stage II of MM1-type sCJD (disease duration
2–5 months) proposed by our previous report,
spongiform change is the most typical and prominent
[5] In contrast, large conﬂuent vacuoles in small coalesc-
ing groups, resembling grape-like clusters, have been
observed in MM2-cortical (MM2C)-type sCJD. In
MM2C-type, this pathological change proceeds slowly
with clinical symptoms, as compared to the MM1-type.
In contrast, the following pathological characteristics of
V180I gCJD have been reported in autopsied cases:
[3,6–12] spongiform change can be observed clearly in
patients with V180I gCJD of not only short disease dura-
tion, but also a long disease duration, as compared to the
MM1- and MM2C-types of sCJD. In V180I gCJD, char-
acteristic spongiform changes are observed in the mor-
phology of vacuoles, which are called various-sized and
non-conﬂuent (VaSNoC) vacuoles [13]. In comparison
to sCJD, gliosis and neuronal loss are generally milder in
V180I gCJD. The condition is also characterized by
weaker, synaptic-type PrP immunoreactivity.
However, no studies have investigated the correlation
between vacuole morphology and duration of disease in
V180I gCJD, and the pathological progression of V180I
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gCJD, especially in terms of how spongiform change
occurs remains unclear. In this study, we aimed to clarify
the pathological progression by examining the size and
number of vacuoles and dispersion of vacuole size (varia-
tion in vacuolar size) of V180I gCJD for each disease




The clinical features of the six patients with V180I gCJD
included in the study are shown in Table 1. Mean age at
onset was 79.1 § 5.2 years (mean § standard deviation
(SD), range: 73–87 years), and mean duration of disease
was 47.8 § 38.5 months (mean § SD, range: 10–
102 months) and symptoms progressed slowly. PSWC
was not observed by EEG. As regard to the cranial mag-
netic resonance imaging examination, T2-weighted
imaging revealed swelling of the cerebral cortex, and dif-
fusion-weighted imaging (DWI)-examined cases showed
high-signal areas mainly in the cerebral cortex and basal
ganglia.
Five patients with sCJD (three with the MM1-type
and two with the MM2C-type) were also investigated as
representative cases of CJD. The clinical features of the
patients with sCJD are shown in Table 2.
Macroscopic ﬁndings in V180I gCJD cases
Mean brain weight before formalin ﬁxation was 888.3 §
206.0 g (mean § SD, range: 600–1150 g). Representative
macroscopic ﬁndings for patient 5 with disease duration
of 101 months are shown in Fig. 1. In this case, although
markedly high diffuse atrophy was observed in the cere-
brum, the precentral gyrus was relatively preserved
(Fig. 1A). Coronal cut surface ﬁndings also revealed
highly diffuse atrophy, and cortical thinning and severe
white matter atrophy were noted (Fig. 1B). The hippo-
campus (Fig. 1B) and the brainstem (Fig. 1C) were well
preserved. The color tone of the substantia nigra and the
locus coeruleus were well preserved (Fig. 1C). The cere-
bellum was preserved (Fig. 1D).
Although the degree of the cerebral atrophy of each
case depended on disease duration, there were essentially
similar ﬁndings in all patients regarding the cerebellum
and brainstem.
Microscopic ﬁndings in V180I gCJD cases
Microscopic ﬁndings of the frontal neocortex of
patients 1 through 6 are shown in Figure 2. A high
degree of spongiform change was extensively observed.
The morphology of spongiform changes showed VaS-
NoC vacuoles. Mild-to-severe tissue rarefaction was
observed dependent on disease duration, but neurons
relatively remained. There were similar ﬁndings at the
temporal, parietal, and occipital neocortices. In all
patients, the degrees of neuronal loss and gliosis were
mild compared to the ﬁndings in the sCJD cases. Neu-
rons remained despite a disease duration of 101 and
102 months (Fig. 2E, F). The approximate degree of
neocortical pathological ﬁndings in the six patients
with V180I gCJD as observed with HE staining and
immunostaining, is shown in Table 3. In all patients,
the neuropil was well preserved and spongiform
change was mild in the hippocampus, subiculum, and
parahippocampal gyrus in comparison to that in the
cerebral cortex. Microscopic ﬁndings of the hippocam-
pus (CA1) and cerebellum of patient 5 are shown in
Figure 3. In the hippocampus, neurons were well pre-
served. Gliosis was mild and there was limited vacuo-
lation. In patients 1 through 4, mild gliosis was found
in the basal ganglia, thalamus, and amygdala, but there
was no neuronal loss. The cerebral white matter was
well preserved. In contrast, in patients 5 and 6, moder-
ate gliosis and mild neuronal loss were found in the
basal ganglia, thalamus, and amygdala. Severe tissue
rarefaction and gliosis were found in the cerebral white
matter. In the cerebellum, limited to mild spongiform
change was noted in the molecular layer, without thin-
ning. The granule-cell layer was also well preserved, as
were Purkinje cells (Fig. 3B). In all patients, the brain-
stem was generally well preserved against neuronal
loss and gliosis.
Microscopic ﬁndings in sCJD cases
Microscopic ﬁndings of the frontal neocortex of patients
7 through 11 are shown in Fig. 4. Spongiform change is
noted. Fine small round vacuoles with clear boundaries
were observed in MM1-type sCJD (Fig. 4A–C). Large
conﬂuent vacuoles in grape-like clusters were observed
in MM2C-type sCJD (Fig. 4D, E).
Quantitative analysis of cerebral cortical pathology
In the present study, observations and measurement of
the major diameters of vacuoles in patients with V180I
gCJD and patients with sCJD (three MM1-type patients
and two MM2C-type patients) at the frontal, temporal,
parietal, and occipital neocortices were quantitatively
analyzed. There was a signiﬁcant difference among
V180I gCJD and the MM1-type sCJD and MM2C-type
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comparisons were performed with the Steel-Dwass test
for each patient. Table 4 shows the total number, mean
major diameters, and the coefﬁcient of variation of mea-
surable and clear vacuoles in all patients. Fig. 5 shows
the box-whisker plot of the vacuole major diameter for
each patient.
Comparison of vacuoles observed in V180I gCJD
No signiﬁcant differences were observed in the vacuo-
lar major diameters of the cerebral neocortex among
patient 1 through 6 in multiple comparisons (Fig. 5)
(each was P > 0.05; Steel-Dwass test). In V180I
gCJD, the vacuole size showed similar major diameter
regardless of disease duration (Fig. 5). No signiﬁcant
difference was observed in the number of vacuoles
depending on the duration of the disease; however,
the number of vacuoles tended to decrease as the dis-
ease duration became longer (Table 4). The major
diameter of the vacuoles observed with V180I gCJD
was 9.86 § 4.42 mm (mean § SD). In V180I gCJD,
there was no apparent difference in the coefﬁcient of
variation of vacuolar major diameter in each patient.
Therefore, in V180I gCJD, no apparent dispersion in
vacuole size was observed regardless of disease dura-
tion (Table 4).
Table 2. Clinicopathological ﬁndings of the three patients with MM1 type and two patients with MM2C type sporadic Creutzfeldt–Jakob
disease.
Patient 7 Patient 8 Patient 9 Patient 10 Patient 11
Type of CJD MM1 MM1 MM1 MM2C MM2C
Clinical features
Age at onset 88 82 80 68 67
Age at death 88 82 81 68 67
Sex Female Male Female Male Male
Family history ¡ ¡ ¡ ¡ ¡
Total disease duration 4 months 5 months 5 months 5 months 5 months
Initial symptoms Left hemiparesis Disorientation Aphasia, right
hemiparesis
Dementia Dementia
Major symptoms and signs Dementia, dysbasia Dementia Right hemiparesis,
dementia
Dementia Dementia
Cerebral cortical dysfunction at
early disease stage
+ + + + +
Visual symptoms at early disease
stage
¡ ¡ ¡ ¡ ¡
Parkinsonism at early disease
stage
¡ ¡ ¡ ¡ ¡
Cerebellar symptoms at early
disease stage
¡ ¡ ¡ ¡ ¡
Myoclonus + + + + +
Akinetic mutism state (Time to
reach)
+ (1 month) + (3 month) + (2 month) + (5 months) + (5 months)
Cause of death Pneumonia Pneumonia Respiratory failure Respiratory failure Respiratory failure
MRI study
MRI study + (2 months after
the onset)
+ (1 months after the
onset)
+ (3 months after
the onset)
+ (5 months after
the onset)




+ (cerebral cortex) + (cerebral cortex) + (cerebral cortex) + (cerebral cortex) + (cerebral cortex)
Cerebral white matter lesion ¡ ¡ ¡ ¡ ¡
CSF study
NSE (ng/mL) 29.9 145.4 126.3 N.E. 22.4
14-3-3 protein (mg/mL) 4044 4014 12250 N.E. N.E.
Tau (pg/mL) 2400 > 1200 27870 N.E. N.E.
EEG study
PSWC + + + + +
Slowing + + + + +
PrP gene analysis
Codon 129 polymorphism Met/Met Met/Met Met/Met Met/Met Met/Met
Codon 219 polymorphism Glu/Glu Glu/Glu Glu/Glu Glu/Glu Glu/Glu
Pathological ﬁndings
Brain weight (g) 910 960 940 1300 1385
Spongiform degeneration Widely Widely Widely Widely Widely
in the cerebral cortex observed observed observed observed observed




Neuroﬁbrillary tangles Braak stage II/III Braak stage II/III Braak stage II Braak stage I Braak stage I
Senile plaques CERAD C CERAD 0 CERAD 0 CERAD 0 CERAD 0
Western blot analysis of PrP Type 1 Type 1 Type 1 Type 2 Type 2
DWI, diffusion-weighted image; NE, not examined; NSE, neuron-speciﬁc enolase; EEG, electroencephalogram; PSWC, periodic sharp-wave complexes; Met,
methionine; Val, valine; Glu, glutamic acid; CJD, Creutzfeldt–Jakob disease; CSF, cerebrospinal ﬂuid; MRI, magnetic resonance imaging; PrP, prion protein;
CERAD, Consortium to Establish a Registry for Alzheimer’s disease
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Comparison of vacuoles in V180I gCJD and sCJD
The vacuolar major diameters in patients with V180I
gCJD (patients 1–6) were larger than those in patients
with the MM1-type (patients 7–9) and the difference was
statistically signiﬁcant (Fig. 5) (each was P < 0.05; Steel-
Dwass test). The major diameter of the vacuoles observed
in patients with the MM1-type was 5.94 § 1.99 mm
(mean § SD). By contrast, the vacuolar major diameter
in patients with V180I gCJD was not signiﬁcantly differ-
ent from that of patients with the MM2C-type (Fig. 5)
(each was P > 0.05; Steel-Dwass test). The major diame-
ter of the vacuoles observed in patients with the MM2C-
type was 12.86§ 11.19 mm (mean§ SD). The coefﬁcient
of variation of vacuolar diameter was generally highest in
the MM2C-type, followed by V180I gCJD, and the
MM1-type (Table 4). Therefore, the dispersion in vacuole
major diameter was relatively larger in the MM2C-type,
followed by V180I gCJD, and the MM1-type. The num-
ber of vacuoles observed was the largest in V180I gCJD,
followed by the MM1-type, and was the lowest in the
MM2C-type (Table 4).
Discussion
In the present study, we compared vacuolar features
according to disease duration of V180I gCJD, as well as
between V180I gCJD and sCJD cases (MM1-type,
MM2C-type). The results revealed that V180I gCJD
showed no statistically signiﬁcant change in vacuolar
major diameter despite disease duration. Furthermore,
the vacuole size observed in V180I gCJD was larger than
that observed in MM1-type sCJD, and the difference was
statistically signiﬁcant; in addition, unlike the vacuoles
Figure 1. Macroscopic ﬁndings in patient 5. (A) the lateral aspect
of the left cerebral hemisphere. The arrowhead indicates the cen-
tral sulcus. (B) the left coronal section of the frontotemporal lobe
through the anterior commissure from the posterior side. (C) the
horizontal cut surface of the brainstem, from the left to the mid-
brain, pons, and medulla oblongata. (D) the sagittal division
plane of the cerebellar vermis.
Figure 2. Microscopic ﬁndings of frontal lobe HE staining in patients with V180I genetic Creutzfeldt–Jakob disease (CJD) (A: patient 1, B:
patient 2, C: patient 3, D: patient 4, E: patient 5, F: patient 6). Spongiform change is noted. However, neuronal loss and gliosis are mild
compared to in sporadic CJD (MM1-type, MM2C-type). Even in patients 5 and 6, neurons remain. Scale bars: 100 mm HE, hematoxylin
and eosin.
Table 3. The approximate degree of neocortical pathological







Patient 1 Severe Moderate Mild Mild
Patient 2 Severe Moderate Mild Mild
Patient 3 Severe Moderate Mild Moderate
Patient 4 Severe Moderate Mild Moderate
Patient 5 Moderate Severe Moderate Severe
Patient 6 Moderate Severe Severe Severe
gCJD, genetic Creutzfeldt–Jakob disease.
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found in MM2C-type sCJD, no conﬂuent vacuole was
remarkable. The major diameter of the vacuole seen in
the MM1-type was relatively uniform; however, the
major diameter in V180I gCJD was relatively more var-
ied than that in the MM1-type. In addition, the major
diameter of the vacuoles seen in the MM2C-type was
generally more varied than that in the MM1-type and
V180I gCJD.
The clinical features of the six patients examined in
the present study were consistent with those previously
reported [2–4]. The pathological examination of 17
patients with CJD revealed that neuronal loss and gliosis
are directly proportional to disease duration, whereas
spongiform change is inversely proportional to disease
duration [14]. However, in that report, the CJD disease
type was not described. The results of our present study
showed that in V180I gCJD, the size of vacuoles and
dispersion of vacuole size did not change, regardless of
disease duration. This is considered to be a characteristic
ﬁnding in the pathological progression of V180I gCJD.
In this study, for the ﬁrst time, various-sized vacuoles
were observed in V180I gCJD, and the dispersion of vac-
uole size was larger than that in the MM1-type and
smaller than that in the MM2C-type, with the differences
being statistically signiﬁcant.
To date, no conclusion on the localization of vacuoles
in CJD has been reached. However, electron microscopy
revealed that vacuoles exist in neurons in human CJD
[15], and electron microscopy of V180I gCJD revealed
membrane-bound intracellular extranuclear vacuolar
inclusions in residual neurons [10]. It is thought that
vacuoles are likely to be present in neuronal cell bodies
and some of their neurites, such as dendrites, and ante-
rior and postsynaptic terminals.
The ﬁndings of the size were similar for any duration
of disease in V180I gCJD, suggesting the possibility that
expansion of vacuole diameter did not result in tissue
rarefaction. Based on our results, the pathological pro-
gression of V180I gCJD may be explained by the follow-
ing four mechanisms: 1. At some point of the disease
course, vacuoles formed in neurons. 2. The vacuoles did
not become larger and their number did not become
increased. However, neurons with vacuoles slowly
diminished. As neurons diminished, rarefaction of the
neuropil slowly occurred. 3. Then, similar size vacuoles
were formed in the neurons that did not previously have
them. 4. Because neuronal loss progresses very slowly, at
this time, the total number of vacuoles did not signiﬁ-
cantly differ depending on the duration of the disease.
However, when the disease duration becomes long, neu-
ronal loss progresses, the number of neurons that have
vacuoles decreases, and so the total number of vacuoles
Figure 3. Microscopic ﬁndings of HE staining of the hippocampus
(CA1) (A) and cerebellum (B) in patient 5. Mild neuronal loss, glio-
sis, and spongiform change are shown. Scale bars: 100 mm HE,
hematoxylin and eosin.
Figure 4. Microscopic ﬁndings of frontal lobe HE staining in patients 7–11 (A: patient 7, B: patient 8, C: patient 9, D: patient 10, E: patient
11). Fine vacuoles are observed in MM1-type sporadic Creutzfeldt–Jakob disease (sCJD) (A–C). Large conﬂuent vacuoles are observed in
MM2C-type sCJD (D, E). Scale bars: 100 mm HE, hematoxylin and eosin.
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also gradually decreases. Neuronal loss and rarefaction of
the neuropil lead to pathological progression of V180I
gCJD, such as tissue rarefaction and decrease in cerebral
weight. The difference in morphology of vacuoles seen in
V180I gCJD and MM1-type and MM2C-type sCJD may
be due to the biochemical difference of PrP, as shown,
for instance, with Western blot analysis. We previously
hypothesized that unknown factors may be acting pro-
tectively against the rapid progression of the clinical
course and the development of pathological involvement
associated with V180I gCJD [3,6,18]. Moreover, in
V180I gCJD, we speculate the possibility that the amount
of PrP accumulated is small because immunoreactivity of
PrP is weak and the neurotoxicity of PrP may be lower
than that of sCJD. The mechanism involved in the vacu-
olation of CJD remains unknown. However, based on
the present observations, the possibility was speculated
that the size, number, and dispersion of vacuoles may
inﬂuence the progression of neuronal loss, at least in
part.
We should note, as a limitation to this study that arti-
facts in the specimens associated with ﬁxation, prepara-
tion, and staining may have affected the actual features.
In addition, spongiform change and oligodendrocyte
perivacuoles may be difﬁcult to distinguish. Moreover,
blindness could not be maintained because the form of
the vacuole varies depending on the type of CJD disease.
In conclusion, VaSNoC vacuoles were observed in
patients with V180I gCJD, and the statistical analysis
showed that the number and size of vacuoles did not
change with disease duration. In our speculation, these
pathologic observations seem to inﬂuence the clinical
progression of V180I gCJD.
Materials and methods
This study was approved by the Ethics Committee of
Aichi Medical University.
Subjects
In the present study, we included six consecutive autop-
sied patients with V180I gCJD, whose pathological exami-
nation was performed at the Institute for Medical Science
of Aging, Aichi Medical University. All patients were Japa-
nese, and none had a family history of prion disease. We
followed protocols for prion gene analysis and Western
blot analysis of PrP as previously reported [16]. Typing of
PrP was performed based on the sCJD classiﬁcation sys-
tem proposed by Parchi et al. [17]. In all six patients with
V180I gCJD, genetic analysis was performed, and a valine
to isoleucine mutation was conﬁrmed in PrP gene codon
180. In patient 3, codon 129 showed methionine/valine
heterozygosity, and the valine polymorphism existed on a
different allele of the V180I mutation. In patients 1, 2, 4, 5,
and 6, codon 129 showed methionine/ methionine homo-
zygosity. Codon 219 showed glutamic acid/ glutamic acid
homozygosity in all cases. Western blot analysis of the










Patient 1 V180I gCJD 10 1202 9.92 § 4.11 (3.12–34.37) 0.41
Patient 2 V180I gCJD 20 1347 9.94 § 5.26 (3.12–37.50) 0.53
Patient 3 V180I gCJD 21 1250 9.97 § 4.46 (3.12–34.37) 0.45
Patient 4 V180I gCJD 33 1088 9.74 § 4.46 (3.12–29.69) 0.46
Patient 5 V180I gCJD 101 726 9.77 § 3.842 (3.12–26.56) 0.39
Patient 6 V180I gCJD 102 1166 9.75 § 4.22 (3.12–29.68) 0.43
Patient 7 sCJD (MM1) 4 947 5.99 § 1.93 (1.56–15.62) 0.32
Patient 8 sCJD (MM1) 5 965 6.16 § 1.93 (3.12–17.19) 0.31
Patient 9 sCJD (MM1) 5 1142 5.63 § 2.00 (1.56–15.62) 0.36
Patient 10 sCJD (MM2C) 5 452 13.06 § 12.76 (3.12–85.94) 0.97
Patient 11 sCJD (MM2C) 5 505 12.68 § 9.57 (3.12–93.75) 0.76
CJD, Creutzfeldt–Jakob disease; g, genetic; s, sporadic.
Coefﬁcient of variation signiﬁes the evaluation of dispersion of vacuole size.
Figure 5. Comparison of vacuolar diameters in all patients with
V180I genetic Creutzfeldt–Jakob disease (gCJD), and MM1-type
and MM2C-type sporadic CJD by box-and-whisker plots of vacu-
ole major diameter. The horizontal line inside each box indicates
the median value, and the length of the box is the interquartile
range (25th–75th percentile). The extremes of the whiskers con-
tain 95% values. Open circles indicate outliers.
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PrPs revealed a characteristic pattern in all patients with
V180I gCJD. A diglycoform band could not be detected,
and the molecular weight of the nonglycoform band was
equivalent to type 2 PrP, but was slightly greater than the
band characteristic of sCJD. The cases of patient 33, 4
[13], and 66 have been previously reported. We included
ﬁve patients with MM1-type and MM2C-type as repre-
sentative cases of CJD; the CJD classiﬁcation of these cases
was conﬁrmed by PrP gene analysis and Western blot
analysis. Because in the patients with MM1-type sCJD
with disease duration more than 11 months, clear vacuoles
could not be observed due to tissue rarefaction [5], we
could not compare them to patients with MM1-type sCJD
with disease duration that corresponded to that of the
patients with V180I gCJD that we studied. For this reason,
we compared the vacuolar ﬁndings of the cases that were
at Stage II of cerebral cortical pathology with the most
marked and apparent vacuolization reported [5], and
were at similar ages with the V180I gCJD cases that we
examined. We included all three patients with MM1-type
sCJD that met these investigation requirements in the
pathological examination performed at our institute. No
mutation was noted in the PrP gene. Codon 129 showed
methionine/ methionine homozygosity and codon 219
showed glutamic acid/ glutamic acid homozygosity in all
cases. Western blot analysis of PrP revealed a pattern of
type-1 PrP. MM2C-type was examined in patient with the
same disease duration as MM1-type. We included all two
patients with MM2C-type sCJD whose disease duration
was similar to that of the MM1-type sCJD cases. No muta-
tion was noted in the PrP gene. Codon 129 showed methi-
onine/ methionine homozygosity and codon 219 showed
glutamic acid/ glutamic acid homozygosity. Western blot
analysis of PrP revealed a type-2 PrP pattern.
Histopathological examination
Autopsy was performed on the whole brain and tissues
were ﬁxed with 20% neutral buffered formalin for
1 month. The brain tissue block was ﬁxed with 95% for-
mic acid for 1 h to inactivate PrP. Sections of 8-mm
thickness were mounted, deparafﬁnized, dehydrated, and
stained. For routine neuropathological examination, the
sections were stained with hematoxylin and eosin (HE),
Kl€uver–Barrera (KB), and modiﬁed Gallyas-Braak silver
staining. Immunohistochemical analysis of selected sec-
tions was performed with antibody 3F4 against PrP
(Dako, Glostrup, Denmark, mouse monoclonal, diluted
1:100) after hydrolytic autoclaving to retrieve the anti-
gen. The PrP immunostaining protocol using the En
Vision ampliﬁed method (EnVision plus kit, Dako) was
conducted as previously described [19,20]. Anti-b-pro-
tein (Dako, mouse monoclonal, diluted 1:1000), anti-
human GFAP antibody (Dako, mouse monoclonal,
diluted 1:1000), anti-Iba-1 antibody (WAKO, rabbit
monoclonal, diluted 1:400), anti-CD68 antibody (Dako,
mouse monoclonal, diluted 1:200), and phosphorylated-
tau (Innogenetics, Ghent, Belgium, AT-8, mouse mono-
clonal, diluted 1:3000) immunostaining were also used
as appropriate. Immunostained sections were lightly
counterstained with Mayer’s hematoxylin.
Pathologic investigation of the vacuole ﬁndings was
performed in the following cerebral cortical regions, as
referred to in the investigation by Parchi et al. [17]: the
frontal (middle frontal gyri), temporal (middle temporal
gyri), parietal (inferior parietal lobule), and occipital (lat-
eral occipital gyrus) neocortices. At these four sites, HE-
stained specimens were observed at 200 £ magniﬁcation
in all patients. For each site, one ﬁeld of representative
view was printed on paper and the major diameter of
each vacuole was measured manually. The number of
vacuoles measured in the frontal, parietal, temporal, and
occipital neocortices were summated as the total number
of vacuoles as shown in Table 4. In the irregularly shaped
or conﬂuent vacuoles, we measured the maximum diam-
eter. The indistinct vacuoles without clear boundary
were excluded from the measurement.
Statistical analysis
The Bartlett test was used, and we conﬁrmed that the
vacuolar size did not follow a normal distribution in any
of the patients. To compare the vacuole major diameters
of all patient, we used the Kruskal-Wallis test with post-
hoc multiple comparisons using the Steel-Dwass test.
Evaluation of dispersion of vacuole size in the data was
performed using the coefﬁcient of variation. Signiﬁcance
was deﬁned as a P value of < 0.05. All statistical analyses
were performed with EZR (Saitama Medical Center, Jichi
Medical University, Saitama, Japan; http://www.jichi.ac.
jp/saitama-sct/SaitamaHP.ﬁles/statmedEN.html; Kanda,
2012), which is a graphical user interface for R (The R
Foundation for Statistical Computing, Vienna, Austria,
version 2.13.0). More precisely, it is a modiﬁed version
of R commander (version 1.6-3) designed to add statisti-
cal functions frequently used in biostatistics [21].
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